To gain insight into the cellular readout of DNA methylation, we established a strategy for systematically profiling the genome-wide distribution of chromatin-interacting factors. This enabled us to create genomic maps for the methyl-CpG-binding domain (MBD) family of proteins, including disease-relevant mutants, deletions, and isoforms. In vivo binding of MBD proteins occurs predominantly as a linear function of local methylation density, requiring functional MBD domains and methyl-CPGs. This interaction directs specificity of MBD proteins to methylated, CpG-dense, and inactive regulatory regions. In contrast, binding to unmethylated sites varies between MBD proteins and is mediated via alternative domains or protein-protein interactions. Such targeting is exemplified by NuRD-complex-mediated tethering of MBD2 to a subset of unmethylated, active regulatory regions. Interestingly, MBD3 also occupies these sites, but like MBD2, binding is independent of the presence of hydroxymethylation. These functional binding maps reveal methylationdependent and -independent binding modes and revise current models of DNA methylation readout through MBD proteins.
INTRODUCTION
In higher eukaryotes, DNA methylation is a covalent modification of cytosine bases associated with transcriptional repression. Recent advances generated base-pair resolution maps for this modification in several organisms, including Arabidopsis, human, and mouse (Cokus et al., 2008; Lister et al., 2009; Stadler et al., 2011) . This unprecedented detail refined our view of the genomic distribution and dynamic behavior of DNA methylation and identified features of methylomes. In comparison, our current knowledge on how DNA methylation is interpreted and how it influences genome regulation is incomplete.
Based on their ability to bind methylated DNA in vitro, the family members of methyl-CpG-binding domain (MBD) proteins are primary candidates for the readout of DNA methylation (Meehan et al., 1989; Hendrich and Bird, 1998) . Protein interaction studies and in vitro experiments have led to a model in which MBD1, MBD2, MBD4, and MeCP2 recruit chromatin remodelers, histone deacetylases, and methylases to methylated DNA, leading to transcriptional repression (Nan et al., 1998; Ng et al., 1999) . Furthermore, alternative functions for MBD proteins have been proposed in various processes, including transcript splicing and chromatin compaction, but also gene activation (Young et al., 2005; Yasui et al., 2007; Chahrour et al., 2008) . MBD3, a component of the nucleosome remodeling and histone deacetylase (NuRD) complex, is the only member of this family lacking specificity toward methyl-CpGs in vitro due to mutations in the MBD domain Saito and Ishikawa, 2002) . A recent report suggested, however, that MBD3 binds 5-hydroxymethylcytosine, the product of active demethylation by the TET family of proteins (Yildirim et al., 2011) .
With the exception of MBD3, single deletions of Mbd1, Mbd2, and Mbd4 result in mild developmental phenotypes, suggesting a redundant function for MBD proteins (Hendrich et al., 2001; Martín Caballero et al., 2009) . Mutations in the most-studied MBD protein, MeCP2, cause a neurological disorder known as Rett syndrome in females and are lethal in males (Amir et al., 1999) . MeCP2 is highly expressed in the postnatal brain (Skene et al., 2010 ), yet transcriptome profiling of MeCP2 null mouse brains did not reveal a clear picture of direct target genes (Tudor et al., 2002) .
Largely due to lack of specific antibodies suitable for chromatin immunoprecipitation (ChIP), limited information exists on the genomic binding of MBD proteins. This, in turn, hindered our ability to relate in vivo binding behavior with DNA methylation, chromatin, and gene activity in detail. Moreover, classical ChIP approaches do not provide a direct comparison of protein variants and mutants that would address the contribution of individual protein domains toward genomic localization.
To generate functional binding maps for the MBD protein family, we have devised a system that combines biotin tagging with controlled and homogenous expression of the protein of interest through repetitive targeting of the same genomic site.
Importantly, this set-up provides a platform to investigate the functional requirement of protein domains and even single amino acid residues for binding to chromatin in vivo. With this approach, we have generated 29 different genome-wide profiles of MBD proteins and their corresponding isoforms or disease related mutants in mouse embryonic stem (ES) cells and derived somatic cell types. This data set enabled us to contrast the binding logics of different MBD proteins and relate them to base-pair resolution DNA methylomes, the presence of 5-hydroxymethylcytosine, and distinct histone modifications. Our analysis reveals qualitatively and quantitatively that the majority of binding that is observed for wild-type MBD1, MBD2, MBD4, and MeCP2 is directed toward methylated regions of the genome. This occurs in a direct and linear dependency on the local density of methylated CpGs, regardless of underlying genomic features. Importantly, methylation-dependent MBD protein enrichment at promoters coincides with repression of the linked gene. Mutations within MBD domains lead to loss of binding specificity to methylated sites, similar to that observed for wild-type proteins in ES cells lacking DNA methylation. These mutant binding profiles further unmask DNA-methylation-independent target sites, which largely differ between MBD family members and rely on their domain composition.
Taken together, these functional binding maps reveal complex binding modes for this protein family and revise current models of gene repression through MBD proteins.
RESULTS

Combined Genomic Targeting and Biotin Tagging for Iterative Binding Analysis of Chromatin and DNA Interacting Factors
To monitor genomic binding for the MBD protein family and selected variants, we employed a recombinase-mediated, genomic targeting approach to ensure controlled and homogenous expression of biotin-tagged proteins of interest from a single defined genomic site. This allows stringent streptavidinbased immunoprecipitation of the biotin-tagged factors in mouse ES and derived neuronal cells ( Figure 1A and Figures S1A-S1E).
Next, we separately inserted expression cassettes for all members of the MBD protein family ( Figure 1B ) and monitored expression levels by comparing wild-type and biotin-tagged cell lines ( Figures 1C, S1F , and S1G). Purification of biotintagged MBD proteins isolated established cofactors, which validated correct interactions with binding partners such as the NuRD complex ( Figures 1C and S1H ), Zhang et al., 1999) . These interactions were further confirmed in differentiated neurons and by complex purifications utilizing antibodies raised against members of the NuRD complex . We further verified nuclear localization for all tagged MBD domain proteins in stem cells and differentiated neurons ( Figures 1D and 1E ) (Lewis et al., 1992; Hendrich and Bird, 1998) .
We conclude that tagged MBD domain proteins that are expressed as single-copy transgenes from the same ectopic site show nuclear localization and protein complex interactions similar to that of the endogenous proteins.
Genomic Mapping in Pluripotent and Somatic Cells Reveals Conserved Binding of MBD Proteins to Densely Methylated Regions
To identify genomic binding sites, we performed ChIP with biotin-tagged MBD proteins in mouse ES cells followed by high-throughput sequencing. Visual inspection of resulting MBD1, MBD2, MBD4, and MeCP2 binding profiles illustrated peaks at regions of dense DNA methylation such as methylated CpG islands, which we further verified by quantitative PCR (Figures 2A and S2A) . This result is in line with binding of MBD proteins to methylated DNA in vitro (Lewis et al., 1992; Hendrich and Bird, 1998) . In contrast, MBD3 shows no visible enrichment at methylated islands, in accordance with in vitro studies reporting that its MBD domain is mutated and unable to bind methylated DNA (Saito and Ishikawa, 2002) .
Given that somatic differentiation entails expression changes of endogenous MBD proteins ( Figures S2B and S2C ), we next asked whether binding to methylated CpG islands is conserved upon loss of pluripotency and commitment to a somatic cell fate. To address this question, we profiled genome-wide MBD protein binding in neuronal cells derived from ES cells carrying biotintagged MBD proteins. Binding profiles at methylated CpG islands show identical enrichments between ES and neuronal cells, compatible with the lack of methylation changes at these sites ( Figure S2D ) (Mohn et al., 2008) .
To quantify the relationship between DNA methylation and MBD protein binding, we took advantage of single base-pair DNA methylation maps that we recently generated in the identical mouse ES cell clone and derived neuronal cells (Stadler et al., 2011) . We calculated the percentage of methylation for individual CpGs and the actual methylation density for a genomic region by combining methylation percentages with the density of CpG dinucleotides ( Figure 2B ). The resulting methylation density reflects the local concentration of methylated CpGs as the bona fide substrate for proteins that bind methylated DNA ( Figure 2C ).
Regions enriched for MBD proteins show irregular shape and length, creating a binding pattern that is incompatible with conventional peak calling methods (Figures 2A and S2D) . Thus, to comprehend the relationship between MBD protein enrichment and methylation properties, we binned the genome into 1-kilobase-sized windows and then selected the highest-and lowest-ranked windows based on MBD protein enrichment for further analysis (see Experimental Procedures). This revealed that all MBD proteins, except MBD3, preferentially bind methylated CpG-rich sequences. CpG-poor regions are weakly bound even when methylated, indicating that methylation density is a key determinant for genome-wide recruitment (Figures 2D and S2E) . This becomes evident when MBD protein enrichment for the entire data set is ranked by DNA methylation density and vice versa (Figures 2E and S2F) . Dependency on methylation density is further illustrated by comparing methylated and unmethylated CpG islands of similar CpG density ( Figure S2G) . Surprisingly, MBD2 and MBD4 show a notable binding at unmethylated CpG islands, a finding that we explore with functional mutants further below. Importantly, binding to methylated islands is conserved between MBD1, MBD2, MBD4, and MeCP2, but not MBD3, implicating a functional MBD domain as a critical factor in localization ( Figure 2D ). In line with this observation, bound regions are shared between pluripotent and differentiated cells, and binding is thus conserved between cell types ( Figures S2H and S2I ).
To test whether protein interactions and genomic binding depend on expression levels, we expressed biotin-tagged MBD2 and MeCP2 from the same genomic locus but under control of the weaker CMV promoter, which leads to 6-fold reduced expression and decreased protein levels. Though this reduces the overall strength of the signal as expected, we nevertheless detect similar interactions and genomic binding, indicating that binding behavior of MBD proteins is largely independent of abundance ( Figures S2J and S2K) .
De novo methylation during differentiation occurs mostly at CpG-poor regions, therefore resulting in limited increase of local methylation density ( Figure S2L ) (Mohn et al., 2008; Stadler et al., 2011) . However, we observe that CpG-dense regions gaining methylation upon differentiation show coinciding increase in MBD protein binding. This is, for example, the case for a somatic DMR at the Gnas-imprinted gene cluster or at CpG island borders ( Figures 2F and 2G ). These borders attract methylation during differentiation even though the island itself remains unmethylated ( Figures S2M and S2N This quantitative relation enables prediction of MBD protein binding to genomic elements based on methylation density alone. We first analyzed promoters, exons, introns, and repetitive elements with varying levels of DNA methylation and CpG density ( Figure 3B ). Average methylation density is highest for exons and lowest for CpG-rich promoters (HCP), as expected. Repeats, introns, intermediate (ICP), and low-CpG promoters (LCP) show similar average methylation densities though with qualitative differences ( Figure 3B ). At repeats, introns, and LCPs, methylation percentage is high and CpG density is low throughout the majority of elements. However, within ICPs, methylation and CpG density are highly variable, as reported previously (Weber et al., 2007) (Figures S3H and S3I) . Global analysis across all elements revealed that binding of MBD proteins is more frequent at exons and a subset of promoters while less frequent at repetitive DNA. Enrichment at exons is compatible with general elevated methylation density at the majority of coding sequences but appears independent of transcriptional activity ( Figures 3C and S3B-S3E ). For the remaining genomic sites, we could predict MBD protein binding behavior primarily through binning based on local methylation density. This is the case for repetitive elements that are typically low in CpG density while highly methylated. Only a few notable exceptions that have retained higher CpG density-mostly members of the endogenous retrovirus family, such as intracisternal A particles (IAP)-display higher methylation densities concomitant with higher frequency of MBD protein occupancy (Figures 3D, S3F, and S3G and Table S2) .
At gene promoters, increased binding is most notable at promoters with intermediate CpG content (ICP) for all MBD proteins ( Figure 3B and Table S1 ). A subset of ICP promoters is methylated, and indeed, MBD binding occurs to this group. (Figures 3E, S3H, and S3I) . Low CpG content (LCP) promoters, however, show only negligible enrichment for MBD proteins despite being methylated, likely due to their low CpG density ( Figure 3B ). Despite the absence of DNA methylation, we observed again a notable binding of MBD2 and MBD4 at high CpG content (HCP) and unmethylated ICP promoters, similar to the binding preferences of MBD3 (Figures 3B and 3E) . Notably, ranking promoters by methylation density results in contrasting MBD protein and RNA polymerase II enrichments, linking MBD protein abundance to gene regulation in vivo ( Figures 3F and S3J) .
To relate MBD binding to other chromatin components, histone marks, and transcription factors, we calculated a correlation matrix using ES cell data sets from various sources ( Figure 3G ). Unsupervised clustering of this matrix identified two major groups. One consists mostly of histone marks and features associated with active chromatin, such as methylation of lysine 4 on histone H3, P300 occupancy, and DNaseI hypersensitivity (DHS)-a measure of transcription factor binding to regulatory regions (Dunham et al., 2012) . The second group is represented by increased methylation density and consequently MBD1, MBD2, MBD4, and MeCP2 enrichment. Interestingly, we also observed that MBD protein localization also correlates with active chromatin marks and 5-hydroxymethylcytosine (5hmC) ( Figure 3G ).
To detect the presence of additional binding cues otherwise masked by the strong dependency on methylation density, we normalized MBD1, MBD2, MBD4, and MeCP2 enrichments to methylation density by applying a linear model (see Experimental Procedures). This allowed us to estimate the contribution of sequence or chromatin composition around methylated CpGs. However, throughout all analyzed factors, including inter-CpG distance and enriched sequence motifs, only DHS, activating histone marks (H3K4me1 and H3K27ac), and 5hmC showed minor correlations with a subset of MBD proteins ( Figures S3K  and S3L ). Though not deterministic for general binding behavior, this correlation is in agreement with the recruitment of MBD2 and MBD4 to unmethylated promoters and active chromatin marks, which we noted above (Figures 3B and 3G) .
Recent reports have implicated 5-hydroxymethylcytosine as an alternative cue for the recruitment of MBD3 and MeCP2 (Yildirim et al., 2011; Mellé n et al., 2012) , whereas other contradicting studies report no evidence for recognition of 5hmC in vitro (Jin et al., 2010; Frauer et al., 2011; Hashimoto et al., 2012; Spruijt et al., 2013) . Importantly, genome-wide 5hmC abundance increases with higher methylation density, making it difficult to distinguish 5mC from 5hmC binding in vivo (Figure S3M) . Thus, the observed general correlations of MBD1, MBD2, MBD4, and MeCP2 with 5hmC could simply reflect binding to 5-methylcytosine ( Figure 3G ). Regulatory elements are the only reported incidence in which 5hmC is abundant at sites of reduced methylation (Pastor et al., 2011; Stadler et al., 2011) . MBD3 shows increased binding to a subset of these sites, raising the possibility that 5hmC is involved in recruitment ( Figure S3N ). This model has been proposed for MBD3, and it will be addressed further below (Yildirim et al., 2011) .
Together, these data suggest that additional cues from chromatin modifications or sequence composition are minor and do not influence preference of MBD proteins to methylated sites, whereas additional targeting to unmethylated sites was detected for a subset of MBD proteins.
Functional MBD Domains Are Required for Targeting to Methylation-Dense Regions In Vivo
To test the dependency on methylation recognition, we profiled a set of protein variants with mutated MBD domains. In the case of MeCP2, these include two prominent mutations occurring in patients with Rett syndrome (R106W and R133C) (Amir et al., 1999) . In addition, we introduced amino acid substitutions at conserved residues of the MBD domains from MBD1 (R22C), MBD2 (R181C), and MBD4 (R106C). These mutations have previously been shown to disrupt specificity toward methylated DNA (Free et al., 2001; Ohki et al., 2001; Scarsdale et al., 2011) ( Figure S4A ). Similar to their wild-type counterparts, we inserted the tagged variants into the same genomic site and under the control of the same promoter. Importantly, this ensured that the introduced protein variations are the only experimental difference. We further verified protein integrity and interactions for these variants ( Figure S4B ). To obtain these bins, we ranked ICPs based on methylation density and selected first and fourth quartiles. (F) DNA methylation density separates MBD protein-bound and RNA-Pol-II-bound promoters. Shown are enrichments over background (log 2 ) at promoters ranked by increasing m-CpG density. Promoters are defined as ± 500 bp around the TSS. (G) Unsupervised clustering of correlation coefficients between 25 data sets calculated on 1 kb sliding windows over chromosome 19. Note the two distinct groups that separate active from repressive marks and factors highlighted in blue and red, respectively. See also Figure S3 and Tables S1 and S2.
With the exception of the MeCP2 variant R133C, nuclear localization analysis of MBD mutants reveals loss of staining to DAPI-dense chromocenters ( Figure 4A ). The R133C variant has previously been suggested to localize to chromocenters as a result of remaining methyl-CpG affinity and/or longer residence time on chromatin (Free et al., 2001; Schmiedeberg et al., 2009 ). Yet whether this localization is linked to DNA methylation remained unknown. Chromatin immunoprecipitation sequencing for all MBD mutant proteins reveal a loss of preferential localization to densely methylated regions, as is evident from representative methylated CpG islands ( Figures  4B and S4C) . To obtain a comprehensive view on binding to methylated CpG islands, we extended our analysis to all methylated CpG islands in the ES cell genome. This analysis revealed that binding to these sites was abolished in the presence of point mutations ( Figure 4C ). On a more global scale, our calculations show that the strong positive correlation between DNA methylation density and binding is largely lost in these mutants, suggesting that genomic binding to methylated regions relies on a functional MBD domain ( Figures 4D  and S4D ).
DNA Methylation Is Required for Targeting MBD Proteins to CpG-Dense Chromatin
So far, our results let us hypothesize that DNA methylation density is the main determinant of MBD domain protein targeting. To directly test this, we determined protein binding in cells that lack DNA methylation. We introduced biotin-tagged MBD proteins into Bir-A-positive, Dnmt1, Dnmt3a, and Dnmt3b triple-knockout (TKO) ES cells (Tsumura et al., 2006) . TKO cells are depleted of 5-methylcytosine as well as 5-hydroxymethylcytosine, as measured by liquid chromatography and subsequent mass spectrometry ( Figure S4E ) and in line with previous reports (Tsumura et al., 2006; Williams et al., 2011) . Immunofluorescence experiments show that, although MBD1, MBD2, and MBD4 no longer localize to DAPI-dense chromocenters, MeCP2 retains a similar staining to that observed in wild-type ES cells ( Figure 4E) .
Binding analysis at representative sites and average profiles at CpG islands methylated in wild-type ES cells revealed lack of enrichment for all analyzed MBD proteins in the TKO background. This argues that DNA methylation is a prerequisite for MBD protein binding at these sites ( Figures 4F, 4G , and S4C). Similar observations were made at the genome level, where enrichment at regions with high methyl-CpG content in wildtype ES cells is lost in TKO ( Figures 4H and S4F ).
MeCP2 Binding Modes to Chromatin in the Absence of DNA Methylation
The fact that MeCP2 remains localized at chromocenters in TKO cells suggests that its localization is, in part, directed by methylCpG-independent binding to chromatin. Indeed, the affinity of MeCP2 for chromatin and the relative amount of DNA precipitated by MeCP2 does not differ significantly between wild-type ES and TKO cells and is, in general, three times greater than for other MBD proteins ( Figures S5A and S5B ). In contrast, the amount of precipitated DNA is significantly reduced for MBD1 in TKO compared to wild-type ES cells (Figures S5A and  S5B) . Together, these results imply that the general affinity of MeCP2 to chromatin does not completely rely on specificity toward DNA methylation (Skene et al., 2010) . To gain further insight into DNA-methylation-independent MeCP2 binding, we analyzed how lack of DNA methylation affects genomic binding. Direct comparison of all MeCP2 data sets, including one previously obtained from adult mouse neurons (Skene et al., 2010) , again highlights that recognition of DNA methylation by a functional MBD domain is the main contributor to binding at specific genomic sites, regardless of tissue type or expression level (Figure S5C) . Despite loss of binding to methylation-dense regions, further analysis of MeCP2 recruitment in TKO cells reveals redistribution to regions with increased DNaseI hypersensitivity, histone H3K4me1 marks, and H3K27ac marks ( Figures 5A-5C  and S5D ). This preference for open accessible chromatin is only unmasked in the absence of genomic DNA methylation and is in stark contrast to MBD1, where binding is generally lost in TKO cells ( Figure S5D ). Figure 2B ; (bottom track) histone H3, lysine-4-dimethyl. See also Figure S5 .
Having established the contribution of the MBD domain and DNA methylation for targeting, we next explored whether additional domains affect the genome-wide binding preference of MBD proteins.
A CXXC Domain within MBD1 Mediates Binding to Unmethylated CpGs in the Absence of the MBD Domain MBD1 contains three CXXC domains that have been implicated in mediating binding to unmethylated CpGs (Figures 1B and S5E ) (Jørgensen et al., 2004) . Nevertheless, we did not observe MBD1 binding to unmethylated CpG islands despite the presence of a third CXXC domain (CXXC-3) with strong homology to the CXXC domains of Cfp1 and MLL ( Figure S5F ). Strikingly, this was also observed in the R22C mutant that inactivates the MBD domain and for the wild-type protein in the TKO background ( Figure S5F ), a finding that disagrees with a previous report in mouse fibroblasts (Jørgensen et al., 2004) . Surprisingly, however, deletion of the entire MBD domain results in a strong affinity of the resulting variant toward unmethylated CpG islands as well as concomitant loss of binding to methylated CpG islands (Figures 5D and S5F) . A similar preference was also observed for an MBD1 isoform (MBD1b) lacking CXXC-3 yet with limited enrichment. This supports the notion that the remaining CXXC domains have less affinity toward unmethylated CpGs (Jørgensen et al., 2004) , whereas CXXC-3 dominates binding only in the absence of the MBD domain ( Figures S5E-S5G ).
MBD2 Binding to Unmethylated DNA Requires Interactions with the NuRD Complex
The transcriptional repression domain (TRD) of methyl-CpGbinding proteins is thought to mediate interaction with binding partners and induce transcriptional silencing (Nan et al., 1997; Boeke et al., 2000; Sarraf and Stancheva, 2004) . To investigate how such protein interactions could influence MBD protein targeting, we removed the respective domains in MBD1 and MeCP2 and determined genome-wide binding. These experiments revealed no difference in binding when compared to the full-length proteins, implying that, for MBD1 and MeCP2, the protein interaction domain does not contribute to chromosomal recruitment ( Figures S6A to S6E ).
In the case of MBD2, removal of the TRD domain would also disrupt the MBD domain (Boeke et al., 2000) . Instead, we focused on the testis-specific MBD2t isoform, which lacks the C terminus ( Figure S6A ) (Hendrich and Bird, 1998 ). Importantly we show by immunoprecipitation that this isoform does not interact with NuRD components such as Mi2-beta, HDAC1, and HDAC2 ( Figure 6A ). The genome-wide location of MBD2t to methylated DNA is similar to full-length MBD2 ( Figures 6B  and S6B-S6E) . Importantly, however, and in contrast to MBD2t, full-length MBD2 binds in addition to a subset of unmethylated sites ( Figures 6B-6D and S6F ). This suggests that protein interaction with the NuRD complex is required for binding of MBD2 to a subset of unmethylated regions. That this recruitment does not involve DNA methylation is further supported by the fact that these sites are still occupied by the MBD2 R108C mutant in wild-type ES cells and by wild-type MBD2 in TKO cells (Figures 6D to 6F) . Interestingly, these methylation-independent sites are DNaseI hypersensitive (DHS) (Figures 6D, 6E , and S6F).
They are also low in CpG density and DNA methylation but enriched for H3K4me1 and H3K27ac and thus show all hallmarks of active regulatory regions ( Figure 6E ) (Heintzman et al., 2009; Stadler et al., 2011) . Further examination of MBD2 enrichment at regulatory regions identified methylation-independent binding at active promoters and enhancer elements (Figures S6G and H) . Methylation-independent MBD2 sites further coincide with binding of Mi2-beta and MDB3 in ES cells suggesting a NuRD complex mediated recruitment ( Figures 6D and 6F and Figures  S6G and H) . Importantly, we do not observe localization of NuRD complex members other than MBD2 to methylated sites. This contradicts with current models of MBD2-mediated targeting of NuRD to methylated sites ( Figures 6D, S6G and H) . We further noted that MBD3 displays preference to regions sensitive to DNaseI and positive for H3K4me1 and H3K27ac, comparable to the methylation-independent binding sites of MBD2, suggesting a similar recruitment as part of NuRD ( Figures 6D-6F , S6G, and S6H).
MBD3 has recently been suggested to bind 5hmC and recruit the NuRD complex to these sites (Yildirim et al., 2011) . Sites preferentially co-occupied by MBD2, MBD3, and NuRD in a methylation-independent manner are indeed 5hmC and TET1 positive ( Figures 7A, S7A , and S7B). Importantly however, both MBD2 and MBD3 are still present at the same regions in TKO cells, and binding is thus independent of the presence of 5-methylcytosine and 5-hydroxymethylcytosine ( Figures 7A and S7D ). This functional test argues against a recruitment of NuRD through binding of MBD3 to 5-hydroxymethylcytosine.
Importantly this methylation-independent recruitment of both MBD2 and MBD3 is largely cell type specific, as most binding events occur at tissue-specific regulatory regions ( Figure 7B ) (Stadler et al., 2011) . One potential interpretation of this result is that MBD2 and MBD3 are binding to a subset of regulatory regions as part of NuRD in a tissue-specific manner. This methylation-independent recruitment accounts for almost all MBD3-binding events and for a subset of MBD2-binding events that occur in wild-type cells.
DISCUSSION
The applied approach of controlled expression of tagged proteins via recombinase-based targeting into the same genomic site enabled rigid comparisons between members and variants of a protein family implied in binding methylated DNA. This allowed quantifying and functionally testing the contribution of individual domains and amino acid residues to genomic targeting of MBD proteins in vivo. Furthermore, this strategy is readily applicable to any chromatin-or DNA-binding factors of interest in pluripotent and derived somatic cells.
Our comprehensive binding study for MBD1, MBD2, MBD3, MBD4, and MeCP2 illustrate that, with the exception of MBD3, DNA methylation is the primary determinant of genomic binding for all proteins with a functional MBD domain. Qualitatively, this DNA methylation dependence is in line with the reported in vitro specificity for MBD domain proteins (Meehan et al., 1989; Hendrich and Bird, 1998) and argues that this interaction also explains many, but not all, in vivo binding events. Combining global MBD protein binding profiles with base-pair resolution methylomes (Stadler et al., 2011) enabled us to directly quantify the relation between recruitment and local concentration of methylated cytosines. This identified a linear relationship between MBD protein enrichment and local methylation density for MBD1, MBD2, MBD4, and MeCP2. Furthermore, it enables us to predict MBD protein binding to genomic elements in ES cells and to identify dynamic changes in binding during cellular differentiation, based solely on measuring methylation density. By modeling the binding data to methylation density, we could further exclude additional binding cues from chromatin modifications or sequence composition, arguing against their contribution to MBD domain specificity in vivo. The linear dependency is conserved between proteins with functional MBD domains and between cell types, further arguing that it is an intrinsic behavior of MBD domains. Further direct evidence for this model comes from our studies of mutations in the MBD domain (Amir et al., 1999; Free et al., 2001) , which in all cases abolish this dependency, reminiscent of wild-type protein binding in cells that lack DNA methylation.
Our findings support the concept that MBD proteins play a central role in the cellular readout of DNA methylation. Our finding of a strong negative correlation between MBD binding and promoter activity as well as enhancer accessibility directly supports a role for MBD proteins in DNA methylation-mediated genome regulation. However, while the exact molecular mechanism that translates DNA methylation into transcriptional regulation still needs to be deciphered, the linear relationship between MBD protein recruitment and methylation density is compatible with the finding that cytosine methylation at regions with high CpG content, such as CpG islands, leads to stronger repression than does methylation of CpG-poor sequences (Boyes and Bird, 1992; Nan et al., 1997) . The similar recruitment of different MBD proteins to methylated DNA is further in line with the concept of largely redundant function between MBD proteins in interpreting DNA methylation. This has been proposed as an explanation for the modest phenotypes observed in knockout mice (Martín Caballero et al., 2009) .
Importantly, the genomic binding maps of mutated MBD domain proteins expose additional preferences to a subset of sites that are DNA methylation independent and that differ between MBD proteins.
In the case of MBD2, we observed binding to sites that display DNaseI hypersensitivity and harbor active chromatin marks. Domain deletions in MBD2 argue that recruitment to these sites is likely mediated by interaction with NuRD complex members. Though this supports the observation that MBD2 is part of a particular NuRD complex (MeCP1, MBD2-NuRD), it challenges the model that MBD2 recruits this complex to methylated regions in vivo Zhang et al., 1999) . This is further supported by the absence of other NuRD complex membersexcept for MBD2-at methylated sites. Notably, sites bound by MBD2 in a methylation-independent manner are similarly bound by MBD3 and represent predominantly tissue-specific regulatory elements with dynamic DNA methylation changes during lineage commitment. This finding is in line with a regulatory role of the MBD3-NuRD complex in modulating transcriptional activity, rather than repressing silent genes (Reynolds et al., 2012) , further suggesting similar functions for MBD2-NuRD. Importantly, the same sites are still bound by MBD2 and MBD3 in the absence of 5-methylcytosine and 5-hydroxymethylcytosine, arguing against a role for these cytosine modifications in recruiting the NuRD complex to genomic targets in vivo Zhang et al., 1999; Yildirim et al., 2011) . This finding challenges the concept that the repressive effect of DNA methylation is mediated by the recruitment of chromatin-modifying proteins to methylated DNA by MBD domain proteins.
EXPERIMENTAL PROCEDURES Cell Lines and Cell Culture
Wild-type embryonic stem cells HA36CB1, derived from mixed 129-C57Bl/6 background blastocysts and TKO-133 modified from Dnmt TKO (Tsumura et al., 2006) , were cultivated on feeder cells or 0.2% gelatine coated dishes. ES cell growth medium consisted of DMEM (Invitrogen) supplemented with 15% fetal calf serum (Invitrogen), 13 nonessential amino acids (Invitrogen), 1 mM L-glutamine, LIF, and 0.001% b-mercaptoethanol. Differentiation was performed as previously described (Bibel et al., 2007) . Information on the generation of Bir-A-positive cell lines is in the Extended Experimental Procedures.
Generation of Biotag-MBD Protein Library and Cell Lines
All methyl-CpG-binding protein cDNAs were amplified from a random hexamere reverse transcription cDNA library (Superscript III, Invitrogen) generated from TRIzol total RNA extracts. MBD protein cDNAs were then cloned into pL1-CAGGS-bio-MCS-polyA-1L, pL1-CMV-bio-MCS-polyA-1L, or pCAGGSbio-MCS-IRES-BlasticidinR-polyA. Single amino acid mutations were introduced via quick-change PCR, and domain deletions were generated by PCR or Gibson assembly. Primers used for generating the MBD protein library and detailed cloning strategies are available upon request. Biotin-tagged MBD protein HA36CB1 ES cell lines were obtained by recombinase-mediated cassette exchange (RMCE) as previously described . Resistant clones were initially tested for successful insertions by PCR and Southern blot analysis. Immunoblot and immunofluorescence confirmed homogenous expression of biotin-tagged MBD proteins. TKO 113 clones were electroporated with linearized pCAGGS-bio-cMBD-IRES-BlasticidinR-polyA constructs and selected on Blasticidin for 10 days. Resistant clones were screened for stable and homogenous biotag-MBD protein expression by immunoblot and immunofluorescence analysis.
Biotin-Streptavidin and Antibody-Based Protein Immunoprecipitation Analysis Nuclear proteins from ESC, progenitors, or neurons were enriched by nuclear fractionation. Streptavidin-biotin pull-downs were performed with preblocked (0.1% cold fish skin gelatine) 30 ml Streptavidin-M280 magnetic beads (Invitrogen) in HENG buffer, 150 mM NaCl, at 4 C overnight. Streptavidin magnetic beads were washed three times each 10 min with HENG buffer, 250 mM NaCl, 0.3% NP40, 1 mM DTT, and protease inhibitors at 4 C. Antibody pull-downs were performed as above with slight modifications, and lysates were precleared with protein A or G agarose beads (depending on isotype) for 1 hr, rotating at 4 C. Precleared lysates were incubated overnight with antibodies against NuRD or Sin3A components and subsequently with protein A or G agarose beads for 3 hr. Washing was performed as above with centrifugation between steps. IPs were resuspended in Laemmli buffer prior to SDS-PAGE and western blotting to PVDF membranes. Membranes were blocked with 5% milk or 5% BSA for detection with antibodies or Streptavidin-HRP, respectively. Antibodies and concentrations used are listed in Table S3 .
Biotin-Streptavidin Chromatin Immunoprecipitation
For cross-linking and chromatin extraction, cells were fixed for 10 min with 1% formaldehyde at room temperature and incubated for 10 min on ice in presence of 1.2 M glycine. Cells were harvested and treated for 10 min with 10 mM EDTA, 10 mM TRIS, 0.5 mM EGTA, and 0.25% Triton X-100 and 10 min in 1 mM EDTA, 10 mM TRIS, 0.5 mM EGTA, and 200 mM NaCl with subsequent lysis in 50 mM HEPES, 1 mM EDTA, 1% Triton X-100, 0.1% deoxycholate, 0.1% SDS, and 150 mM NaCl for 2 hr on ice. Crosslinked chromatin was subjected to sonication in a Bioruptor instrument (Diagenode). Streptavdin-M280 magnetic beads were blocked for 1 hr with 0.1% cold fish skin gelatin and 100 ng tRNA. 150-250 mg chromatin were precleared with protein A Dynabeads and incubated with 40 ml blocked streptavidin-M280 magnetic beads overnight at 4 C. Beads were washed with two rounds of 2% SDS, 13 high-salt buffer, 13 LiCl buffer, and two rounds of TE. Beads were treated with RNaseA for 30 min at 37 C and proteinase K for 3 hr at 65 C and were then decrosslinked overnight at 55 C. DNA was purified with phenol-chloroform extraction and ethanol precipitation.
Library Preparation and High-Throughput Sequencing and Data Analysis Sequencing libraries were prepared using custom inline bar-coded adapters (Lefranç ois et al., 2009; Table S4 ) following standard Illumina library preparation kits and protocols. Four samples with different barcodes were mixed at equal molar ratios per pool. Sequencing of library pools was performed on Illumina HiSeq 2000 machines according to Illumina standards. Bar-coded reads were demultiplexed into individual samples (FASTX, http://hannonlab. cshl.edu/fastx_toolkit/), filtered for low-quality reads and adaptor sequences, and mapped to the mouse genome (version mm9) using the BOWTIE algorithm (http://bowtie-bio.sourceforge.net/) allowing for two mismatches and mapping up to 100 different genomic sites per read. For downstream analysis, we converted the reads into the genomic ranges format (GenomicRanges, R), filtered out all reads that mapped to more than one genomic site, and shifted the read position to account for sonication fragment length using the Chip-seq package in R. Finally, we obtained a minimum of 15 million uniquely mapped reads per sample, with sequencing depth for wild-type MBD proteins exceeding 30 million unique reads. Replicates were pooled for subsequent analysis. DNA methylation reads from bisulphite sequencing were processed as described (Stadler et al., 2011) . Detailed information on data processing, genomic coordinates, and data analysis are in the Extended Experimental Procedures.
ACCESSION NUMBERS
All high-throughput sequencing data generated in this study were deposited at NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE39610. Additional data sets used in this study are listed in Table S5 .
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, and five tables and can be found with this article online at http://dx.doi. org/10.1016/j.cell.2013.03.011.
